-
Insights from the MVA-MERS-S Vaccine Trial
A phase 1b clinical trial by a valuable team of researchers explores the safety, immunogenicity, and optimal dosing of MVA-MERS-S, a modified vaccinia Ankara-based candidate vaccine for MERS-CoV.
-
Gut Microbiota and Eating Disorders: A New Frontier in Neuroinflammation Research
Could the gut microbiome be the missing link in understanding eating disorders? A groundbreaking study led by Dr. Sabrina J.P. Huwart, Dr. Nuria Morales-Puerto, and Dr. Amandine Everard (Université catholique de Louvain) sheds light on the interplay between gut microbiota, neuroinflammation, and food reward alterations—a critical factor in the development of eating disorders like anorexia…
-
Enhancing PrEP Adherence Among Young Women in Johannesburg: What Works?
Adherence to HIV pre-exposure prophylaxis (PrEP) remains a challenge among young women in sub-Saharan Africa, despite its proven effectiveness in preventing HIV. A landmark study led by Dr. Jennifer Velloza (University of California, San Francisco) evaluates innovative interventions to improve PrEP adherence in Johannesburg, South Africa.
-
New 10-Year Follow-Up Data from the DREPAGREFFE Trial: Allogeneic Stem Cell Transplantation vs. Standard Care in Sickle Cell Anemia
Recently published in Blood, the DREPAGREFFE-2 trial provides crucial insights into long-term cognitive and cerebrovascular outcomes in children with sickle cell anemia (SCA) and a history of abnormal cerebral velocities.…
-
New Insights into LDH-A and T Cell Differentiation
A recent study published in Blood (Volume 144, Supplement 1, November 5, 2024) explores the role of Lactate Dehydrogenase A (LDH-A) in CD8+ T cell differentiation and its impact on…
-
New Insights from SABCS 2024: Biomarkers and Pembrolizumab in TNBC
At the San Antonio Breast Cancer Symposium (SABCS) 2024, Joyce O’Shaughnessy presented findings from the KEYNOTE-522 trial, a phase 3 study evaluating pembrolizumab in combination with chemotherapy for early-stage triple-negative…
-
Study Highlights Socioeconomic Barriers in Access to Allo-HCT for AML Patients
A study published in Blood on November 5, 2024, reveals how socioeconomic factors influence access to allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) patients. The findings indicate…
-
New Potential Treatment for Sickle Cell Disease: IMA001 Shows Promise
Presented on November 5, 2024, new research highlights the potential of IMA001 as a novel therapeutic approach for Sickle Cell Disease (SCD). The study demonstrated that IMA001 significantly reduced red…
Connecting Medical Expertise through Media